Tocilizumab
Anti-IL-6 receptor monoclonal antibody
- Response rate
- Under investigation
- Onset
- Weeks
- Route
- IV or SC
- Line
- Investigational
- IgM effect
- Reduces SAA/CRP via IL-6 blockade
Evidence summary
Phase III multicenter RCT evaluating efficacy in colchicine-resistant/intolerant FMF. Targets IL-6, which drives SAA production and systemic inflammation. Could be particularly relevant for preventing AA amyloidosis. Results pending.